Natera, Inc. (NASDAQ:NTRA) had its price target reduced by Morgan Stanley from $18.00 to $13.00 in a report published on Monday, Marketbeat Ratings reports. They currently have an overweight rating on the medical research company’s stock.

NTRA has been the topic of several other reports. ValuEngine downgraded shares of Natera from a sell rating to a strong sell rating in a report on Monday, July 24th. Zacks Investment Research downgraded shares of Natera from a buy rating to a hold rating in a report on Thursday, May 11th. BidaskClub downgraded shares of Natera from a hold rating to a sell rating in a report on Tuesday, August 1st. Finally, Canaccord Genuity increased their price objective on shares of Natera from $14.00 to $16.00 and gave the company a buy rating in a report on Wednesday, May 10th. Four equities research analysts have rated the stock with a sell rating and four have issued a buy rating to the company. The stock presently has an average rating of Hold and an average price target of $14.80.

Shares of Natera (NTRA) traded up 2.00% during mid-day trading on Monday, reaching $8.18. 97,634 shares of the company’s stock were exchanged. The company’s 50 day moving average is $10.36 and its 200 day moving average is $9.58. The stock’s market capitalization is $432.57 million. Natera has a 1-year low of $7.35 and a 1-year high of $13.08.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Tuesday, May 9th. The medical research company reported ($0.70) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.61) by $0.09. The company had revenue of $46.90 million for the quarter, compared to analysts’ expectations of $42.82 million. Natera had a negative net margin of 60.89% and a negative return on equity of 101.63%. The business’s revenue for the quarter was down 24.2% on a year-over-year basis. During the same period in the previous year, the business earned ($0.17) earnings per share. Equities research analysts anticipate that Natera will post ($1.98) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by Daily Political and is owned by of Daily Political. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The original version of this news story can be accessed at https://www.dailypolitical.com/2017/08/08/morgan-stanley-lowers-natera-inc-nasdaqntra-price-target-to-13-00.html.

Several large investors have recently modified their holdings of the stock. Russell Investments Group Ltd. acquired a new stake in shares of Natera during the fourth quarter worth approximately $130,000. American International Group Inc. boosted its stake in shares of Natera by 7.1% in the first quarter. American International Group Inc. now owns 16,065 shares of the medical research company’s stock worth $142,000 after buying an additional 1,068 shares during the period. Massachusetts Financial Services Co. MA boosted its stake in shares of Natera by 1.2% in the first quarter. Massachusetts Financial Services Co. MA now owns 16,118 shares of the medical research company’s stock worth $143,000 after buying an additional 194 shares during the period. Goldman Sachs Group Inc. boosted its stake in shares of Natera by 45.3% in the first quarter. Goldman Sachs Group Inc. now owns 17,386 shares of the medical research company’s stock worth $154,000 after buying an additional 5,417 shares during the period. Finally, Alliancebernstein L.P. boosted its stake in shares of Natera by 5.6% in the first quarter. Alliancebernstein L.P. now owns 26,600 shares of the medical research company’s stock worth $236,000 after buying an additional 1,400 shares during the period. Institutional investors and hedge funds own 59.74% of the company’s stock.

Natera Company Profile

Receive News & Ratings for Natera Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera Inc. and related companies with MarketBeat.com's FREE daily email newsletter.